Cantargia AB (STU:7V3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7V3 Cantargia AB STU:7V3
44 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Cantargia AB FFO?

FFO (Funds from operations) only applies to REITs.

STU:7V3
44GF Score
Cantargia AB STU:7V3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Business Description

Other Exchanges CANTA:Sweden
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
44GF Score

Get the complete analysis for STU:7V3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price